QuidelOrtho (NASDAQ:QDEL - Get Free Report) is anticipated to issue its Q2 2025 quarterly earnings data after the market closes on Tuesday, August 5th. Analysts expect the company to announce earnings of $0.01 per share and revenue of $612.36 million for the quarter. QuidelOrtho has set its FY 2025 guidance at 2.070-2.570 EPS.
QuidelOrtho (NASDAQ:QDEL - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.74 earnings per share for the quarter, beating analysts' consensus estimates of $0.61 by $0.13. The business had revenue of $692.80 million during the quarter, compared to analyst estimates of $694.97 million. QuidelOrtho had a negative net margin of 12.07% and a positive return on equity of 4.71%. QuidelOrtho's revenue was down 2.6% compared to the same quarter last year. During the same period last year, the business earned $0.44 EPS. On average, analysts expect QuidelOrtho to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.
QuidelOrtho Stock Up 4.0%
NASDAQ:QDEL traded up $1.06 on Friday, reaching $27.39. 1,163,403 shares of the stock traded hands, compared to its average volume of 1,777,442. The company has a market capitalization of $1.85 billion, a price-to-earnings ratio of -5.51 and a beta of 0.07. The company has a current ratio of 1.20, a quick ratio of 0.66 and a debt-to-equity ratio of 0.70. QuidelOrtho has a 12 month low of $23.77 and a 12 month high of $49.45. The company's fifty day simple moving average is $29.28 and its 200 day simple moving average is $33.81.
Analyst Ratings Changes
A number of research firms have weighed in on QDEL. Wall Street Zen lowered shares of QuidelOrtho from a "buy" rating to a "hold" rating in a research note on Saturday. UBS Group reduced their price objective on shares of QuidelOrtho from $45.00 to $29.00 and set a "neutral" rating for the company in a research note on Thursday, May 8th. Jefferies Financial Group upgraded shares of QuidelOrtho from a "hold" rating to a "buy" rating and set a $44.00 price objective for the company in a research note on Thursday, May 8th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of QuidelOrtho from $38.00 to $25.00 and set an "underweight" rating for the company in a research note on Monday, April 21st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $44.33.
Read Our Latest Analysis on QDEL
Institutional Trading of QuidelOrtho
A number of large investors have recently made changes to their positions in QDEL. Royal Bank of Canada boosted its holdings in shares of QuidelOrtho by 1,218.7% in the first quarter. Royal Bank of Canada now owns 80,193 shares of the company's stock worth $2,803,000 after buying an additional 74,112 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of QuidelOrtho by 10.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 228,398 shares of the company's stock worth $7,987,000 after buying an additional 21,968 shares during the last quarter. Finally, Focus Partners Wealth boosted its holdings in shares of QuidelOrtho by 210.9% in the first quarter. Focus Partners Wealth now owns 20,454 shares of the company's stock worth $715,000 after buying an additional 13,876 shares during the last quarter. 99.00% of the stock is currently owned by institutional investors.
About QuidelOrtho
(
Get Free Report)
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.
Further Reading
Before you consider QuidelOrtho, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and QuidelOrtho wasn't on the list.
While QuidelOrtho currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
